Hematologic Malignancy
Mature B-Cell Non-Hodgkin Lymphoma
CI-CAN-00003259Explore in graph →
Hematologic792 active trials17 approved drugs43 evidence items
- NCIt
- C7056
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003259Explore in graph →
Clinical trials
2,506 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (393)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02933320 | BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia | completed | Phase 1 / Phase 2 | 14 | Cancer Research UKOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT04908059 | Leukemic Phase of ALCL(LEUK-ALCL) | unknown | — | 2 | University Hospital, Strasbourg, FranceOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT04952974 | B-cell Chronic Lymphoid Malignancies Markers(MALYZOMA-II) | unknown | — | 420 | University Hospital, Strasbourg, FranceOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT00794638 | A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 9 | SymBio PharmaceuticalsINDUSTRY | 1 | Jul 2, 2021 | clinicaltrials |
| NCT03869619 | REal World Data in LYmphoma and Survival in Adults(REALYSA) | recruiting | — | 6,000 | Hospices Civils de LyonOTHER | 1 | Jun 28, 2021 | clinicaltrials |
| NCT02323230 | A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL | terminated | Phase 2 | 4 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 1 | Jun 22, 2021 | clinicaltrials |
| NCT04934930 | Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status(FLMRD) | unknown | Phase 2 | 40 | Meir Medical CenterOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT01592981 | Randomised Trial in Waldenstrom's Macroglobulinaemia(R2W) | completed | Phase 2 | 60 | University College, LondonOTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT02945319 | Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma | completed | — | 373 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 1 | Jun 7, 2021 | clinicaltrials |
| NCT03259529 | Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL(BeGeRN) | completed | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jun 7, 2021 | clinicaltrials |
| NCT04913103 | Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL(CLSGMCLPOLA) | not yet recruiting | Phase 2 | 21 | Czech Lymphoma Study GroupOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT04914143 | the Effect of Broken Ganoderma Lucidum Spore Powder on Quality of Life and Immune Function in Patients With Diffuse Large B-cell Lymphoma After Chemotherapy | unknown | N/A | 120 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT03579888 | CD19-Specific T Cells Post AlloSCT | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT00702052 | Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy(PILLAR-1) | completed | Phase 2 | 58 | Novartis PharmaceuticalsINDUSTRY | 1 | May 25, 2021 | clinicaltrials |
| NCT04899570 | Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT02669017 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) | completed | Phase 1 | 183 | ADC Therapeutics S.A.INDUSTRY | 3 | May 19, 2021 | clinicaltrials |
| NCT01234766 | Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma(Fol-BRITe) | completed | Phase 2 | 39 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT01419665 | GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)(ASSIST_FL) | completed | Phase 3 | 629 | SandozINDUSTRY | 26 | May 14, 2021 | clinicaltrials |
| NCT02037256 | Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma | completed | N/A | 23 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 10, 2021 | clinicaltrials |
| NCT00317096 | FCM Versus R-FCM Followed by R-Maintenance or Observation Only | unknown | Phase 3 | 319 | Ludwig-Maximilians - University of MunichOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT01742988 | Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma | completed | Phase 1 | 106 | Curis, Inc.INDUSTRY | 1 | May 6, 2021 | clinicaltrials |
| NCT01363128 | Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | completed | Phase 2 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT01046006 | Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia | completed | Phase 2 | 59 | Meletios A. DimopoulosOTHER | 3 | Apr 30, 2021 | clinicaltrials |
| NCT01497496 | Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | completed | Phase 2 | 29 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT04860674 | A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma | unknown | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 0 | Apr 27, 2021 | clinicaltrials |
| NCT01125293 | Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia | terminated | Phase 1 / Phase 2 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2021 | clinicaltrials |
| NCT04856137 | A Phase I/II Study of Diffuse Large B-cell Lymphoma(DLBL) | not yet recruiting | Phase 1 / Phase 2 | 74 | National Health Research Institutes, TaiwanOTHER | 0 | Apr 23, 2021 | clinicaltrials |
| NCT00536601 | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors | completed | N/A | 174 | Roswell Park Cancer InstituteOTHER | 1 | Apr 22, 2021 | clinicaltrials |
| NCT02128061 | Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+ | completed | Phase 3 | 250 | The Lymphoma Academic Research OrganisationOTHER | 2 | Apr 13, 2021 | clinicaltrials |
| NCT04842318 | Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study | unknown | Phase 4 | 789 | Ruijin HospitalOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT04842487 | R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study | unknown | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 0 | Apr 13, 2021 | clinicaltrials |
| NCT02194751 | Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma | unknown | Phase 2 | 30 | XEME Biopharma Inc.INDUSTRY | 1 | Apr 8, 2021 | clinicaltrials |
| NCT02260804 | To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma | completed | Phase 3 | 258 | CelltrionINDUSTRY | 1 | Apr 8, 2021 | clinicaltrials |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies | terminated | Phase 1 | 2 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT04824950 | Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)(CAMIL) | recruiting | N/A | 87 | Centre Henri BecquerelOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04825899 | Gene Abnormalities and Prognosis in Diffuse Large B-cell Lymphoma | unknown | — | 100 | Fudan UniversityOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04827004 | A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma | unknown | Phase 2 | 30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04705129 | Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL | unknown | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT03800095 | Early Palliative Care for Patients With Haematological Malignancies(CALVI) | unknown | Phase 3 | 140 | University Hospital, Clermont-FerrandOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT04804865 | Secondary Prognostic Index in RefrActory Lymphoma(SPiRAL) | unknown | — | 180 | WepromOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT03000192 | HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life | unknown | — | 3,000 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04342117 | Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL(REAL) | terminated | — | 2 | SecuraBioINDUSTRY | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04476459 | Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL | unknown | Phase 1 / Phase 2 | 33 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04796857 | Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL | unknown | Phase 1 / Phase 2 | 30 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT03197259 | Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National Study(CLLTRegistry) | unknown | — | 1,000 | Fatih Demirkan, MDOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT02165397 | Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia | completed | Phase 3 | 181 | Pharmacyclics LLC.INDUSTRY | 9 | Mar 3, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Jul 8, 2021source: clinicaltrials